

Liver Forum 18

Friday, April 4 - Saturday, April 5, 2025
AC Hotel Reston
1975 Opportunity Way, Reston, VA 20190

DAY 1 AGENDA

8:00 AM	Registration and Breakfast	
9:00 AM	Session I: Welcome and Introductory Remarks	
9:00 AM	Welcome & Forum Overview	<i>Edyth Dwyer & Sehyr Khan, Forum</i>
9:05 AM	Introductory Remarks	<i>Michelle Long, Novo Nordisk Veronica Miller, Forum Arun Sanyal, VCU</i>
9:15 AM	Session II: PEDDL Working Group Update & Toolkit Proposal	
9:15 AM	Moderator: Teresa Wright, GSK & Fady Tanios, Boehringer Ingelheim	
9:15 AM	PEDDL Forward: Driving Patient-Centered Innovation in MASH Drug Development	<i>Michael Betel, Fatty Liver Alliance</i>
9:20 AM	From Ideas to Impact: Our Patient Engagement Journey So Far	<i>Rosemarie Sellati, Regeneron Pharmaceuticals</i>
9:25 AM	Moving Forward: Building the Toolkit for Engagement	<i>Henry Chang, Fatty Liver Foundation</i>
9:30 AM	Open Discussion	<i>All Participants</i>
10:15 AM	Session III: Forum NITs for RLSE Proposal- Focus on Fibrogenesis	
10:15 AM	Moderator: Veronica Miller, Forum & Michelle Long, Novo Nordisk	
10:15 AM	Discussion Framework of Liver Forum Proposal for a New NIT-based RLSE in MASLD	<i>Quentin Anstee, Newcastle University</i>
10:45 AM	Open Discussion	<i>All Participants</i>
11:15 AM	Break	
11:45 AM	Session IV: Data & Analysis Review	
11:45 AM	Moderator: Roberto Calle, Regeneron Pharmaceuticals & Veronica Miller, Forum	
11:45 AM	FCR NIT Literature Review	<i>Richard Haubrich, Forum</i>
12:05 PM	Unicorn Biomarkers	<i>Morten Karsdal, Nordic Bioscience*</i>
12:15 PM	Speakers Q&A	<i>All Speakers</i>
12:30 PM	Lunch	
1:30 PM	Session IV: Data & Analysis Review (Continued)	
1:30 PM	Moderator: Mark Hartman, Eli Lilly and Company & Veronica Miller, Forum	
1:30 PM	Moving ELF Closer to a Reasonably Likely Surrogate Endpoint	<i>Matthew Gee, Siemens Healthineers</i>
1:50 PM	LSM by VCTE as a Reasonably Likely Surrogate Endpoint: Review of the Latest Clinical Evidence	<i>Céline Fournier, Echosens</i>
2:10 PM	Insights into NIT CV from the Pfizer MIRNA Trial	<i>Quentin Anstee, Newcastle University</i>
2:30 PM	Exploratory analysis: ELF components in 4296 and 4492	<i>Michelle Long, Novo Nordisk</i>
2:40 PM	Non-Invasive Tests for Reasonably- Likely Surrogate Endpoints: MRE	<i>Kay Pepin, Resoundant*</i>

2:50 PM	Speakers Q&A	<i>All Speakers</i>
3:10 PM	Open Discussion	<i>All Participants</i>
3:40 PM	Break	
4:10 PM	Session V: Consideration of Non-Fibrogenic Biomarkers	
4:10 PM	Moderator: Quentin Anstee, Newcastle University & Veronica Miller, Forum	
4:20 PM	ctT1 as a Reasonably Likely Surrogate Endpoint in MASH Clinical Trials	<i>Rajarshi Banerjee & Andrea Dennis, Perspectum</i>
4:30 PM	Speakers Q&A	<i>All Speakers</i>
4:35 PM	Session VI: Coming to Consensus on NITs for an RLSE	
4:35 PM	Moderator: Arun Sanyal, VCU & Veronica Miller, Forum	
4:35 PM	What is Meaningful to the Patients?	<i>Henry Chang, Fatty Liver Foundation</i>
4:50 PM	Open Discussion	<i>All Participants</i>
5:20 PM	Session VII: Future of NITs & Day Wrap Up	
5:20 PM	Day Wrap Up	<i>Michelle Long, Novo Nordisk Veronica Miller, Forum Arun Sanyal, VCU</i>
5:30 PM	Adjourn & Evening Reception	
	* indicates remote participation	
DAY 2 AGENDA		
8:00 AM	Registration and Breakfast	
9:00 AM	Session VIII: Stretch Exercise in Statistics	
9:00 AM	Moderator: Mark Hartman, Eli Lilly and Company & Michelle Long, Novo Nordisk	
9:00 AM	Beyond Binay Outcomes	<i>Michael Harhay, University of Pennsylvania*</i>
9:15 AM	Open Discussion	<i>All Participants</i>
9:45 AM	Break	
10:15 AM	Session IX: Defining Progression to Cirrhosis	
10:15 AM	Moderator: Manal Abdelmalek, Mayo Clinic & Hank Mansbach, 89bio	
10:15 AM	Progression to Cirrhosis– Considerations in Operationalizing the Endpoint	<i>Arun Sanyal, VCU</i>
10:30 AM	MAESTRO-NASH Outcomes: Identification of F4 without Biopsy	<i>Becky Taub, Madrigal Pharmaceuticals</i>
10:50 AM	Discussants	<i>Juan G. Abraldes, University of Alberta* Salvador Augustin, Boehringer Ingelheim Meena Bansal, Icahn School of Medicine* Guadalupe Garcia-Tsao, Yale University* Jenn Jones, Sober Livers Mazen Nouredin, Houston Research Institute* Arun Sanyal, VCU Becky Taub, Madrigal Pharmaceuticals</i>
11:35 AM	Session X: Closing Remarks	
11:35 AM	Closing Remarks	<i>Michelle Long, Novo Nordisk Veronica Miller, Forum Arun Sanyal, VCU</i>
11:50 AM	Adjourn & Lunch	
	* indicates remote participation	